Autoantibodies are antibodies that react with self-antigens. They are produced by both tissue and circulating self-reactive B lymphocytes, following cooperation with T helper lymphocytes. Autoimmune hemolytic anemia (AIHA) is defined as the increased destruction of red blood cells (RBCs) in the presence of anti-RBC autoantibodies with or without complement activation.
Warm antibody hemolytic anemia (WAIHA) is an autoimmune disorder characterized by the premature destruction of healthy red blood cells by autoantibodies. It is a common disorder directed against self RBCs. WAIHA is the most common type of autoimmune hemolytic anemia, comprising ∼70–80% of all adult cases and ∼50% of the pediatric cases. More than half of these cases are called primary due to undefined etiology. At the same time, the rest is termed a secondary to lymphoproliferative syndromes, malignant diseases, including chronic lymphoblastic leukemia (CLL), non-Hodgkin’s lymphoma, and solid tumors.
DelveInsight’s ‘Warm Autoimmune Hemolytic Anemia (WAIHA) – Market Insights, Epidemiology and Market Forecast-2030‘ report delivers an in-depth understanding of the disease,historical &forecasted epidemiology as well as the market trends of WAIHAs in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Warm Autoimmune Hemolytic Anemia (WAIHA) from 2017 to 2030 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Geography Covered
- The United States
- EU5 (Germany, France, Italy, Spain and the United Kingdom)
- Japan
Study Period: 2017–2030
View report: https://www.delveinsight.com/sample-request/warm-autoimmune-hemolytic-anemia-waiha-market
Warm Autoimmune Hemolytic Anemia (WAIHA) – Disease Understanding and Treatment Algorithm
Warm Autoimmune Hemolytic Anemia (WAIHA) is an autoimmune disorder characterized by the premature destruction of healthy red blood cells by autoantibodies. It is a common disorder directed against self RBCs which can be idiopathic (primary) or secondary. In w-AIHA, the autoantibodies react optimally with the RBCs at 37°C. In typical cases, no specific antibody can be identified since theyare polyclonal and react with all RBCs tested (pan-reactive), even when w-AIHA complicates a clonal B-cell lymphoproliferative disorder like CLL. The traditional treatment options for WAIHA include corticosteroids, splenectomy,and conventional immunosuppressive drugs.
The DelveInsight Warm Autoimmune Hemolytic Anemia (WAIHA) market report gives the thorough understanding of the Warm Autoimmune Hemolytic Anemia by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Warm Autoimmune Hemolytic Anemia.
Warm Autoimmune Hemolytic Anemia Epidemiology
The Warm Autoimmune Hemolytic Anemia (WAIHA) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Prevalent Cases of AIHA, Diagnosed Prevalence of wAIHA, Type-specific Prevalence of wAIHA, Gender-specific Prevalence of wAIHA) scenario of Warm Autoimmune Hemolytic Anemia (WAIHA) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017–2030.
According to DelveInsight, the total number of prevalent cases of Warm Autoimmune Hemolytic Anemia (WAIHA) in 7 MM was found to be 82,045 in the year 2017.
Warm Autoimmune Hemolytic Anemia Drug Chapters
This segment of the Warm Autoimmune Hemolytic Anemia report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Currently, affected individuals are usually treated with corticosteroid drugs such as prednisone and can usually be well controlled with proper treatment. For individuals who do not respond to corticosteroid therapy or develop intolerable side effects, immunosuppressive drugs may be administered, or surgical removal of the spleen (splenectomy) may be performed. Over the years,however, newer options have become available with considerable evidence of success. They are used mainly in patients who fail to respond to splenectomy, those who relapse after splenectomy, and those who cannot maintain stable hemoglobin levels without unacceptably high doses of corticosteroids.
Download full report: https://www.delveinsight.com/sample-request/warm-autoimmune-hemolytic-anemia-waiha-market
Warm Autoimmune Hemolytic Anemia Market Outlook
The Warm Autoimmune Hemolytic Anemia market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the market of Warm Autoimmune Hemolytic Anemia in 7MM was found to be USD 368 Million in 2017, and is expected to increase during the course of the study period (2017–2030).
The market for Warm Autoimmune Hemolytic Anemia is expected to increase with a CAGR of 5.20% for 7MM. Among the 7MM, the United States accounts for the largest market size of WAIHA, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.
Warm Autoimmune Hemolytic Anemia Drugs Uptake
This section focuses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017–2030. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Request for sample pages: https://www.delveinsight.com/sample-request/warm-autoimmune-hemolytic-anemia-waiha-market
Table of contents:
1. Key Insights
2. Executive Summary
3. SWOT Analysis
4. wAIHA Market Overview at a Glance
4.1. Market Share (%) Distribution of wAIHA in 2017
4.2. Market Share (%) Distribution of wAIHA in 2030
5. Disease Background and Overview
5.1. Introduction
5.2. Types
5.3. Causes
5.4. Signs and Symptoms
5.5. Pathophysiology
5.6. Manifestations
5.7. Diagnosis
- Immunohematological assessment of patients with AIHA
- DAT-negative AIHA
6. Epidemiology and Patient Population
6.1. Key Findings
6.2. KOL Views
6.3. 7MM Total Prevalent Patient Population of wAIHA
6.4. Assumptions and Rationale: 7MM
7. Country Wise-Epidemiology of wAIHA
7.1. The United States
7.1.1. Total Prevalent Cases of AIHA in the United States
7.1.2. Diagnosed Prevalence of wAIHA in the United States
7.1.3. Type-specific Prevalence of wAIHA in the United States
7.1.4. Gender-specific Prevalence of wAIHA in the United States
7.2. EU5
7.2.1. Germany
7.2.1.1. Total Prevalent Cases of AIHA in Germany
7.2.1.2. Diagnosed Prevalence of wAIHA in Germany
7.2.1.3. Type-specific Prevalence of wAIHA in Germany
7.2.1.4. Gender-specific Prevalence of wAIHA in Germany
7.2.2. France
7.2.2.1. Total Prevalent Cases of AIHA in France
7.2.2.2. Diagnosed Prevalence of wAIHA in France
7.2.2.3. Type-specific Prevalence of wAIHA in France
7.2.2.4. Gender-specific Prevalence of wAIHA in France
7.2.3. Italy
7.2.3.1. Total Prevalent Cases of AIHA in Italy
7.2.3.2. Diagnosed Prevalence of wAIHA in Italy
7.2.3.3. Type-specific Prevalence of wAIHA in Italy
7.2.3.4. Gender-specific Prevalence of wAIHA in Italy
7.2.4. Spain
7.2.4.1. Total Prevalent Cases of AIHA in Spain
7.2.4.2. Diagnosed Prevalence of wAIHA in Spain
7.2.4.3. Type-specific Prevalence of wAIHA in Spain
7.2.4.4. Gender-specific Prevalence of wAIHA in Spain
7.2.5. The United Kingdom
7.2.5.1. Total Prevalent Cases of AIHA in the UK
7.2.5.2. Diagnosed Prevalence of wAIHA in the UK
7.2.5.3. Type-specific Prevalence of wAIHA in the UK
7.2.5.4. Gender-specific Prevalence of wAIHA in the UK
7.3. Japan
7.3.1. Total Prevalent Cases of AIHA in Japan
7.3.2. Diagnosed Prevalence of wAIHA in Japan
7.3.3. Type-specific Prevalence of wAIHA in Japan
7.3.4. Gender-specific Prevalence of wAIHA in Japan
8. Treatment and Management of wAIHA
8.1. Sequential approach to treatment options for w-AIHA and common dosing regimens
8.1.1. First-line therapy
8.1.1.1. Corticosteroids
8.1.2. Second-line therapy
8.1.2.1. Splenectomy
8.1.2.2. Rituximab
8.1.2.3. Immunosuppressive drugs
8.1.2.4. Other Options
8.2. British Guidelines for WAIHA treatment
9. Case Study
10. Patient Journey
12. Unmet Needs
13. Emerging Therapies
13.1. Fostamatinib: Rigel Pharmaceuticals
13.1.1. Product Description
13.1.2. Other Development Activities
13.1.3. Clinical Development
13.1.3.1. Clinical Trials Information
13.1.4. Safety and Efficacy
13.2. APL-2: Apellis Pharmaceuticals, Inc.
13.2.1. Product Description
13.2.2. Other Development Activities
13.2.3. Clinical Development
13.2.3.1. Clinical Trials Information
13.2.4. Safety and Efficacy
13.3. M281: Momenta Pharmaceuticals
13.3.1. Product Description
13.3.2. Other Development Activities
13.3.3. Clinical Development
13.3.3.1. Clinical Trials Information
13.3.4. Safety and Efficacy
13.4. IMVT-1401: Immunovant
13.4.1. Product Description
13.4.2. Other Development Activities
13.4.3. Clinical Development
13.4.3.1. Clinical Trials Information
13.4.4. Safety and Efficacy
13.5. ALXN1830/SYNT001: Alexion Pharmaceuticals, Inc.
13.5.1. Product Description
13.5.2. Other Development Activities
13.5.3. Clinical Development
13.5.4. Clinical Trials Information
13.5.5. Product Profile
14. Other Promising Candidates
14.1. BIV009 (Sutimlimab): Sanofi
14.1.1. Product Description
14.1.2. Other Development Activities
14.1.3. Clinical Development
14.1.4. Clinical Trials Information
14.1.5. Safety and Efficacy
14.1.6. Product Profile
15. wAIHA: 7 Major Market Analysis
15.1. Key Findings
15.2. Market Size of wAIHA in 7MM
15.3. KOL Views
16. Market Outlook by Country
16.1. The United States: Market Outlook
16.2. United States Market Size
16.2.1. Total Market Size of wAIHA
16.2.2. Market Size of wAIHA by Therapies
17. EU-5 Countries: Market Outlook
17.1. Germany
17.1.1. Total Market size of wAIHA
17.1.2. Market Size of wAIHA by Therapies
17.2. France
17.2.1. Total Market Size of wAIHA
17.2.2. Market Size of wAIHA by Therapies
17.3. Italy
17.3.1. Total Market Size of wAIHA
17.3.2. Market Size of wAIHA by Emerging Therapies
17.4. Spain
17.4.1. Total Market Size of wAIHA
17.4.2. Market Size of wAIHA by Therapies
17.5. United Kingdom
17.5.1. Total Market Size of wAIHA
17.5.2. Market Size of wAIHA by Therapies
18. Japan: Market Outlook
18.1.1. Total Market Size of wAIHA
18.1.2. Market Size of wAIHA by Therapies
19. Market Drivers
20. Market Barriers
21. Appendix
21.1. Report Methodology
22. DelveInsight Capabilities
23. Disclaimer
24. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Contact us:
Shruti Thakur
info@delveinsight.com
+919650213330
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/